Abstract:AIDS Research and Human RetrovirusesVol. 30, No. S1 Novel Vaccine ConceptsFree AccessLive Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in HumansJinghe Huang, Byong Kang, Adam Wheatley, Sandeep Narpala, Adrian Mcdermott, April Poole, Robert Bailer, Richard Koup, Stephen Migueles, Marc Gurwith, and Mark ConnorsJinghe HuangNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Byong KangNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Adam WheatleyNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Sandeep NarpalaNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Adrian McdermottNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, April PooleNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Robert BailerNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Richard KoupNIAID, NIH, Vaccine Research Center, Bethesda, MD, United StatesSearch for more papers by this author, Stephen MiguelesNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this author, Marc GurwithPaxVax Inc., La Jolla, CA, United StatesSearch for more papers by this author, and Mark ConnorsNIAID/LIR, HIV-Specific Immunity Section, Bethesda, MD, United StatesSearch for more papers by this authorPublished Online:30 Oct 2014https://doi.org/10.1089/aid.2014.5073.abstractAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail OA16.01Background: Induction of durable antibody responses capable of neutralizing diverse HIV-1 isolates is the most important goal in HIV vaccinology. Broad and potent HIV Env-specific antibodies isolated from humans are characterized by binding to conserved sites on Env and by high levels of hypermutation. Live virus recombinant vectors may provide prolonged exposure to transgene-encoded antigen and may more potently drive affinity maturation than non-replicating vectors. We report results of a small Phase 1 trial of mucosal immunization with live adenovirus type 4 encoding influenza H5 HA (Ad4-H5-Vtn) as a model antigen. We explored its ability to induce durable, broad neutralizing antibody responses through upper respiratory tract application.Methods: Live Ad4-H5Vtn (103-108 viral particles (VP)) was administered by tonsillar swab or by nasal spray in a dose escalation study. Controls received (1010 VP) as enteric-coated capsules. Neutralizing antibodies were measured by a pseudotype HA lentiviral vector system. B cells were isolated using fluorescent HA probes. Immunoglobulin genes were cloned for mutation analysis, and re-expressed to measure neutralization potency and breadth.Results: The vaccine was well tolerated and symptoms were consistent with mild URI. Tonsillar and nasal immunizations were the most immunogenic routes inducing neutralizing antibody responses at day 60 (ID50=809 and 666 respectively) which rose during the first 6 months. B cells that expanded early were specific for both H1 and H5 and were directed to the conserved stalk, with H5 HA-monospecific cells expanding by 6 months. The median level of hypermutation was 3.6% compared to germline at week 4 and 7.4% at weeks 34–52. However, some antibodies contained 13–34% mutation and neutralized group 1 and 2 viruses.Conclusions: A single dose of live recombinant Ad4-H5 can induce highly mutated antibodies, suggesting that mucosal administration is a promising platform for the induction of HIV-specific neutralizing antibodies.FiguresReferencesRelatedDetails Volume 30Issue S1Oct 2014 InformationCopyright 2014, Mary Ann Liebert, Inc.To cite this article:Jinghe Huang, Byong Kang, Adam Wheatley, Sandeep Narpala, Adrian Mcdermott, April Poole, Robert Bailer, Richard Koup, Stephen Migueles, Marc Gurwith, and Mark Connors.Live Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in Humans.AIDS Research and Human Retroviruses.Oct 2014.A44-A44.http://doi.org/10.1089/aid.2014.5073.abstractPublished in Volume: 30 Issue S1: October 30, 2014PDF download

HIV Type 1 B′/C Recombinant (CRF07_BC) in Virologic Noncontrollers Elicits Neutralizing Antibodies Against Heterologous but Not Autologous Viruses

Sequence Characteristics of Hiv-1 B' Envelope Proteins and Its Potential Correlation with Broadly Neutralizing Activity

Identification of A Novel Hiv-1-Neutralizing Antibody from A Crf07_bc-Infected Chinese Donor

Profiling the neutralizing antibody response in chronically HIV-1 CRF07_BC-infected intravenous drug users naïve to antiretroviral therapy

Profiles of Neutralizing Antibody Response in Chronically Human Immunodeficiency Virus Type 1 Clade B '-Infected Former Plasma Donors from China Naive to Antiretroviral Therapy

Isolation of monoclonal neutralizing antibody from a HIV-1-infected Chinese donor

Neutralization Sensitivity of Hiv-1 Subtype B' Clinical Isolates from Former Plasma Donors in China

Coexistence of potent HIV-1 broadly neutralizing antibodies and antibody-sensitive viruses in a viremic controller.

Type-specific and Cross-Reactive Neutralizing Antisera Against HIV Elicited by V3-peptide Heptalysine Octomers.

Cross-neutralizing antibody profile of Chinese HIV-1-infected individuals and the viral envelope features from elite neutralizers

A VH1-69 Antibody Lineage from an Infected Chinese Donor Potently Neutralizes HIV-1 by Targeting the V3 Glycan Supersite.

Virus Evolution and Neutralization Sensitivity in an HIV-1 Subtype B ' Infected Plasma Donor with Broadly Neutralizing Activity

Identification of a novel broadly HIV-1-neutralizing antibody from a CRF01_AE-infected Chinese donor.

Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses

Combined Approach of Vaccine and Antiviral Drugs Can Achieve Better Protection in Nhp Model Against Heterologous Shiv Challenges

Neutralization Sensitivity of HIV-1 CRF07_BC From an Untreated Patient With a Focus on Evolution Over Time

Genetic and Neutralization Sensitivity of Diverse HIV-1 env Clones from Chronically Infected Patients in China

Induction of Broadly Neutralizing Antibodies to Hiv-1 Via Dna Motif Immunization

Live Adenovirus Type 4 Recombinants Induce Durable Neutralizing Antibody Responses to Influenza H5 with High Levels of Somatic Hypermutation in Humans

Two Distinct Broadly Neutralizing Antibody Specificities of Different Clonal Lineages in a Single HIV-1-Infected Donor: Implications for Vaccine Design

Characterization of a VRC01-like antibody lineage with immature VL from an HIV-1 infected Chinese donor